Edwards Lifesciences Corporation (EW) Revenue History
Annual and quarterly revenue from 1999 to present
EW Revenue Over Time (1999–2025)
EW Revenue Growth History
23 of 26 years with positive growth- FY1999 revenue growth
- N/A
- FY2000 revenue growth
- -11.2%
- FY2001 revenue growth
- -13.9%
- FY2002 revenue growth
- +1.7%
- FY2003 revenue growth
- +22.2%
- FY2004 revenue growth
- +8.3%
- FY2005 revenue growth
- +7.1%
- FY2006 revenue growth
- +3.9%
- FY2007 revenue growth
- +5.2%
- FY2008 revenue growth
- +13.4%
- FY2009 revenue growth
- +6.8%
- FY2010 revenue growth
- +9.5%
- FY2011 revenue growth
- +16.0%
- FY2012 revenue growth
- +13.2%
- FY2013 revenue growth
- +7.7%
- FY2014 revenue growth
- +13.6%
- FY2015 revenue growth
- +7.4%
- FY2016 revenue growth
- +18.8%
- FY2017 revenue growth
- +15.9%
- FY2018 revenue growth
- +8.4%
- FY2019 revenue growth
- +16.8%
- FY2020 revenue growth
- +0.9%
- FY2021 revenue growth
- +19.3%
- FY2022 revenue growth
- +2.9%
- FY2023 revenue growth
- -6.9%
- FY2024 revenue growth
- +8.6%
- FY2025 revenue growth
- +11.5%
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $1.57B | +13.3% |
| Q3 2025 | $1.55B | +14.7% |
| Q2 2025 | $1.53B | +10.6% |
| Q1 2025 | $1.41B | +6.2% |
| Q4 2024 | $1.39B | +9.4% |
| Q3 2024 | $1.35B | +8.9% |
| Q2 2024 | $1.39B | +7.0% |
| Q1 2024 | $1.33B | -8.9% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
EW's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
EW Revenue Analysis (1999–2025)
Current Revenue & Growth
As of June 22, 2026, Edwards Lifesciences Corporation (EW) generated trailing twelve-month (TTM) revenue of $6.07 billion, reflecting strong growth of +13.3% year-over-year. The most recent quarter (Q4 2025) recorded $1.57 billion in revenue, up 1.1% sequentially.
Historical Growth Trajectory
EW's 5-year compound annual growth rate (CAGR) stands at +6.7%, indicating steady revenue expansion. The 3-year CAGR of +4.1% is below the 5-year average, signalling a growth deceleration in recent years. Edwards Lifesciences Corporation's highest annual revenue of $6.07 billion was recorded in 2025, an all-time high.
Revenue by Segment
EW's revenue is primarily driven by Transcatheter Heart Valves (74%), Surgical Heart Valve Therapy (17%), and Transcatheter Mitral And Tricuspid Therapies (9%). With over half of revenue concentrated in Transcatheter Heart Valves, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including MDT (+6.9% YoY), ABT (+6.4% YoY), and BSX (+19.9% YoY) — EW has outperformed the peer group in revenue growth. Compare EW vs MDT →
EW Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EWCurrent | $6.1B | +13.3% | +6.7% | 27.0% | |
 MDT | $33.5B | +6.9% | +3.0% | 17.8% | |
 ABT | $42.0B | +6.4% | +5.6% | 16.3% | |
 BSX | $20.1B | +19.9% | +15.2% | 19.8% | |
 SYK | $25.1B | +11.2% | +11.8% | 19.5% | |
 ZBH | $8.2B | +9.2% | +6.1% | 16.5% |
EW Historical Revenue Data (1999–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $6.07B | +11.5% | $4.74B | 78.1% | $1.64B | 27.0% |
| 2024 | $5.44B | +8.6% | $4.32B | 79.5% | $1.38B | 25.3% |
| 2023 | $5.01B | -6.9% | $3.97B | 79.3% | $1.43B | 28.5% |
| 2022 | $5.38B | +2.9% | $4.22B | 78.3% | $1.70B | 31.6% |
| 2021 | $5.23B | +19.3% | $4.01B | 76.6% | $1.61B | 30.8% |
| 2020 | $4.39B | +0.9% | $3.29B | 74.9% | $1.30B | 29.5% |
| 2019 | $4.35B | +16.8% | $3.19B | 73.4% | $1.20B | 27.6% |
| 2018 | $3.72B | +8.4% | $2.80B | 75.2% | $1.09B | 29.3% |
| 2017 | $3.44B | +15.9% | $2.55B | 74.3% | $1.01B | 29.4% |
| 2016 | $2.96B | +18.8% | $2.16B | 72.8% | $815.5M | 27.5% |
| 2015 | $2.49B | +7.4% | $1.81B | 72.6% | $575.9M | 23.1% |
| 2014 | $2.32B | +13.6% | $1.69B | 72.8% | $487.2M | 21.0% |
| 2013 | $2.05B | +7.7% | $1.50B | 73.4% | $433.0M | 21.2% |
| 2012 | $1.90B | +13.2% | $1.39B | 73.3% | $396.7M | 20.9% |
| 2011 | $1.68B | +16.0% | $1.22B | 72.5% | $329.1M | 19.6% |
Full Stock Analysis
Deep dive into EW consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
27+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
EW — Frequently Asked Questions
Quick answers to the most common questions about buying EW stock.
Is EW's revenue growth accelerating or slowing?
EW revenue growth is holding steady at +13.3% year-over-year. TTM revenue is $6.1B. The current growth rate closely tracks the 5-year CAGR of +6.7%, signalling consistent execution.
What is EW's revenue history from 1999 to 2026?
Edwards Lifesciences Corporation (EW) revenue history spans 1999 to 2026. TTM revenue as of 2026 is $6.1B, growing at +13.3% YoY. The 5-year CAGR is +6.7%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is EW's long-term revenue growth rate (CAGR)?
Edwards Lifesciences Corporation's 5-year revenue CAGR of +6.7% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +13.3% is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for EW.
Why does EW's quarterly revenue fluctuate?
EW quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Edwards Lifesciences Corporation's revenue data from 1999 to 2026 shows full historical quarterly detail on this page.
How is EW's revenue distributed by segment?
EW reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does EW's revenue compare to industry peers?
Edwards Lifesciences Corporation (EW) with TTM revenue of $6.1B and +13.3% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.